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Abstract
Background: The OmcB protein is one of the most immunogenic proteins in C. trachomatis and C.
pneumoniae infections. This protein is highly conserved leading to serum cross reactivity between the
various chlamydial species. Since previous studies based on recombinant proteins failed to identify a
species specific immune response against the OmcB protein, this study evaluated an in silico predicted
specific and immunogenic antigen from the OmcB protein for the serodiagnosis of C. trachomatis infections.
Results: Using the ClustalW and Antigenic programs, we have selected two predicted specific and
immunogenic regions in the OmcB protein: the N-terminal (Nt) region containing three epitopes and the
C-terminal (Ct) region containing two epitopes with high scores. These regions were cloned into the
PinPoint Xa-1 and pGEX-6P-1 expression vectors, incorporating a biotin purification tag and a glutathione-
S-transferase tag, respectively. These regions were then expressed in E. coli. Only the pGEX-6P-1 has been
found suitable for serological studies as its tag showed less cross reactivity with human sera and was
retained for the evaluation of the selected antigens. Only the Ct region of the protein has been found to
be well expressed in E. coli and was evaluated for its ability to be recognized by human sera. 384 sera were
tested for the presence of IgG antibodies to C. trachomatis by our in house microimmunofluorescence
(MIF) and the developed ELISA test. Using the MIF as the reference method, the developed OmcB Ct
ELISA has a high specificity (94.3%) but a low sensitivity (23.9). Our results indicate that the use of the
sequence alignment tool might be useful for identifying specific regions in an immunodominant antigen.
However, the two epitopes, located in the selected Ct region, of the 24 predicted in the full length OmcB
protein account for approximately 25% of the serological response detected by MIF, which limits the use
of the developed ELISA test when screening C. trachomatis infections.
Conclusion: The developed ELISA test might be used as a confirmatory test to assess the specificity of
serological results found by MIF.
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Background
Chlamydiaceae, intracellular obligate bacteria, is divided
into two genera Chlamydia and Chlamydophila. The only
species infecting humans in the genus Chlamydia  is
Chlamydia trachomatis, the most common cause of genital
tract infections. The genus Chlamydophila contains six spe-
cies. Chlamydophila pneumoniae and occasionally, Chlamy-
dophila psittaci and Chlamydophila abortus [1,2] (also called
Chlamydophila psittaci serovar1) are human pathogens. C.
pneumoniae and C. psittaci cause respiratory tract infec-
tions whereas C. abortus causes abortion. While serology is
the current method of choice in routine clinical laborato-
ries for the diagnosis of acute C. pneumoniae infections [3],
nucleic acid amplification tests [4,5] represent the meth-
ods of choice for the diagnosis of acute C. trachomatis
infections. The usefulness of serology in the diagnosis of
C. trachomatis infections has been reviewed [6,7]. It is gen-
erally accepted that serology is used for the serodiagnosis
of complications in ascending chlamydial infections and
in seroepidemiological studies [8-10].
Several methods were used for the serological diagnosis of
chlamydial infections. The microimmunoflurescence
(MIF) test, which detects antibodies to chlamydial ele-
mentary bodies, has long been considered to be the gold
standard for the serodiagnosis of chlamydial infections.
However, this method lacks standardization. Further-
more, cross reactivity between the chlamydial species,
which affects the specificity of this test, was reported in the
literature [11-13]. These cross reactions between the
chlamydial species would, therefore, hamper the diagno-
sis and the interpretation of chlamydial serology. Several
enzyme linked immunosobent assays (ELISA) have been
developed. Promising results were obtained with these
tests using as antigen purified chlamydial elementary bod-
ies devoided of the genus specific lipopolysaccharide
(LPS) [14-16]. However, serum cross reactivity persisted
due to the presence of other genus specific epitopes as well
as residual contaminants. The use of chemically or recom-
binant antigens seems to be attractive to improve chlamy-
dial serodiagnosis. This approach requires the
identification of the most immunodominant antigens in
human C. trachomatis infections. Proteomic and immuno-
blot analyses demonstrated that the most immunogenic
chlamydial components comprise the genus specific LPS,
the major outer membrane protein (MOMP) and the
OmcB protein (also called outer membrane protein 2,
OMP2) [17-23]. The MOMP protein contains 4 surface
exposed variable domains that are the major sites of anti-
genicity [24]. The variable domains I, II and IV contain the
primary serovar determining epitopes, allowing C. tracho-
matis classification into serovars [25].
The OmcB protein is the second most abundant outer
membrane protein in Chlamydiae. The omcB gene of C. tra-
chomatis comprises 1641 bp and encodes a 60 kDa pro-
tein. The translated amino acid sequence reveals a
relatively basic protein containing 24 cysteine residues
[26]. It has been suggested that disulphide cross linked
polymers of the OmcB protein are the functional equiva-
lent of peptidoglycan in other Gram negative bacteria,
forming a disulphide cross linked network with the peri-
plasmic domains of MOMP and other membrane pro-
teins which may contribute to the considerable structural
stability of C. trachomatis elementary bodies [27].
Although this protein is a major immunogen in chlamy-
dial infections, it was shown to be localized at the inner
surface of the outer membrane complex [28]. In fact, in
vivo as a result of host defence reactions during the course
of the infection, determinants of previously inaccessible
bacterial proteins may be released from disintegrated cell
walls and become exposed to B cell antigen receptors. Fur-
thermore, upon protein unfolding after limited proteoly-
sis, previously inaccessible linear motifs can be exposed to
serve as B cell epitopes and become immunogenic [29].
Recently, Fadel et al. [30] suggested that the OmcB protein
of C. trachomatis is surface exposed and that it functions as
a chlamydial adhesion protein since anti-OmcB antibody
inhibits in vitro infectivity of C. trachomatis.
The OmcB protein is highly conserved among the chlamy-
dial species [31] so that serum cross reactivity with the
OmcB of C. pneumoniae is frequently seen [29,32,33]. In
order to identify a species specific humoral immune
response directed against C. trachomatis OmcB protein,
Mygind et al. [33] prepared three overlapping fusion pro-
teins and found that immunodominant linear epitopes
recognized by human antibodies were distributed
throughout the entire sequence of the OmcB protein. In
the current study, we used internet accessible computer
based algorithms to assess their ability to predict OmcB
species specific epitopes recognized in human chlamydial
infections. Using the ClustalW and Antigenic programs,
we have selected two predicted specific and immunogenic
regions [34,35]. These regions were cloned into the Pin-
Point Xa-1 and pGEX-6P-1 expression vectors incorporat-
ing a biotin purification tag (BPT) and a glutathione-S-
transferase tag (GST), respectively, to facilitate the purifi-
cation of the recombinant proteins. Our main objective
was to develop an ELISA test based on an in silico predicted
specific and immunogenic antigen from the OmcB pro-
tein for the serodiagnosis of C. trachomatis infections and
to evaluate the antigen using a considerable number of
sera. Furthermore, we aimed at assessing the ability of the
two vectors to express recombinant fusion proteins detect-
ing species specific antibodies to C. trachomatis without or
with minimal reactivity with tags.BMC Microbiology 2008, 8:217 http://www.biomedcentral.com/1471-2180/8/217
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Methods
Bioinformatics
Alignments of OmcB proteins of C. trachomatis, C. pneumoniae 
and C. psittaci and determination of percentage identity
OmcB protein sequences of C. trachomatis serovars as well
as C. pneumoniae and C. psittaci were retrieved from the
NCBI database in FASTA format. The Needle program was
used to perform global pair wise alignments of sequences
for determining percentage identities between OmcB pro-
teins and/or peptides http://www.ebi.ac.uk/emboss/
align/. C. trachomatis serovar E was used as the reference
sequence for all alignments performed. The ClustalW pro-
gram was used to construct multiple sequence alignment
using the default parameters http://www.ebi.ac.uk/Tools/
clustalw/. Accession numbers of protein sequences used
of C. trachomatis serovars, C. pneumoniae and C. psittaci are
shown in table 1.
Antigenicity prediction
Antigenicity prediction was performed using the Anti-
genic program of the Pasteur institute http://bioweb.pas
teur.fr/seqanal/interfaces/antigenic.html. This program
predicts potentially antigenic regions of a protein, using
the method of Kolaskar and Tongaonkar [36].
Determination of the molecular weight
The molecular weights (Mw) of the selected regions were
determined by the computer pI/Mw tool http://
www.expasy.ch/tools/pi_tool.html, [37].
Generation of recombinant proteins
Bacterial strains, plasmids and media
C. trachomatis serovar E was used as a template for PCR
reaction. Escherichia coli strain Top 10 was used as a clon-
ing host. The E. coli strain BL21 (DE3), which contains the
structural gene for T7 RNA polymerase under the control
of the lac promoter, was used for protein expression. The
pMOS blue blunt ended cloning kit (Amersham) was
used as a cloning vector. The plasmids PinPoint Xa-1
(Promega), and pGEX-6P-1 (Amersham) under the con-
trol of the tac promoter, were used as expression vectors.
The PinPoint Xa-1 vector places the insert fragment in
frame with an N terminal region encoding a polypeptide
of 123 amino acid fusion tag that becomes biotinylated in
E. coli by an endogenous biotin ligase activity resulting in
the addition of a single biotin to lysine at residue 88 of the
polypeptide. The pGEX-6P-1 expression vector places the
insert fragment in frame with an N terminal region encod-
ing the GST. E. coli strains were grown in Luria Bertani
(LB) medium, supplemented with 100 μg/ml ampicillin
when plasmid maintenance was required. In the case of
the biotinylated fusion proteins, expressed using the Pin-
Point Xa-1 vector, 2 μM of biotin were also included in the
medium.
DNA preparation of C. trachomatis
Chlamydial DNA was extracted using an in house method
based on proteinase K treatment. Briefly, 100 μl of the cul-
tured C. trachomatis serovar E was centrifuged at 14000
rotations per minute (rpm) for 30 minutes. The superna-
tant was discarded and the pellet was washed twice with
phosphate buffered saline (PBS). The DNA was released
with proteinase K (Invitrogen) in lysis buffer (10 mM Tris-
HC1 pH 8, 1 mM EDTA). Proteins were digested at 55°C
for 1 hour. The enzymatic reaction was then stopped by
incubation at 98°C for 10 minutes.
Cloning and construction of the overexpression plasmids
The parts of the omcB gene, encoding the selected parts of
the OmcB protein by the bioinformatics tools, were
amplified by PCR from genomic DNA of C. trachomatis
serovar E. The PCR mixture, which was made up to 50 μl
with sterile water, contained 1× PCR buffer (50 mM Tris-
HCl pH 8.3, 10 mM KCl, 5.0 mM (NH4)2SO4, and 2.0
Table 1: Percentage identities determination between the OmcB proteins, the Nt and Ct regions within the chlamydial species.
Chlamydial species Serovars Protein accession numbers OmcB protein Nt region  Ct region
C. trachomatis A REFSEQ: YP_328263 97.5% (539/553) 18.3% (101/553) 7.2% (40/553)
B EMBL: CAA37588 98.5% (539/547) 18.5% (101/547) 7.3% (40/547)
C GenBank: AAA23159 98.7% (540/547) 18.5% (101/547) 7.3% (40/547)
D REFSEQ: NP_219955 97.5% (539/553) 18.3% (101/553) 7.2% (40/553)
E EMBL: CAA39396 100% (547/547) 19.0% (104/547) 7.3% (40/547)
F GenBank: AAA23154 99.1% (542/547) 18.6% (102/547) 7.3% (40/547)
G/H/K Swiss-Prot: Q548P6 98.5% (539/547) 18.5% (101/547) 7.3% (40/547)
I/J Swiss-Prot: Q933I7 98.5% (539/547) 18.5% (101/547) 7.3% (40/547)
L1/L2/L3 Swiss-Prot: P21354 97.8% (535/547) 18.3% (100/547) 7.3% (40/547)
C. pneumoniae EMBL: CAA37590 71.5% (398/557) 8.8% (49/557) 4.3% (24/556)
C. psittaci EMBL: CAA37592 70.9% (397/560) 8.2% (46/560) 4.7% (26/557)
Nt: N-terminal, Ct: C-terminal, Percentage identities were determined using the Needle program. C. trachomatis serovar E was used as the 
reference sequence for all alignments performed.BMC Microbiology 2008, 8:217 http://www.biomedcentral.com/1471-2180/8/217
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mM MgCl2); 0.5 mM of each primer; 0.2 mM each dATP,
dCTP, dGTP and dUTP; 1.25 U of the high fidelity Pfu
DNA polymerase (Promega, France); and 5 μl of prepared
DNA extract from C. trachomatis serovar E. PCR was per-
formed using the Gene-Amp PCR System 9700 (Perkin
Elmer Cetus) under the following conditions: an initial
cycle at 95°C for 5 minutes, followed by 35 cycles of dena-
turation at 94°C for 30 seconds, annealing at 55°C for 30
seconds, and elongation at 72°C for 30 seconds, with a
final cycle at 72°C for 7 minutes.
For cloning of the Nt region in the PinPoint Xa-1 vector,
the phosphorylated amplification product was cloned
into the pMOS blue blunt ended cloning kit. The amplifi-
cation product using the forward and U19 primers intro-
duces a BamHI site that is used to generate a 3' cohesive
end in order to direct the cloning of the insert in the Pin-
Point Xa-1 vector. Thus, the amplification product was
digested by BamHI, purified, phosphorylated and then
ligated to a previously NruI/BamHI linearised and purified
PinPoint Xa-1 vector.
For cloning of the Ct region in the PinPoint Xa-1 vector,
the amplification product was purified, phosphorylated
and ligated to a previously NruI linearised, purified and
dephosphorylated PinPoint Xa-1 vector. The correct ori-
entation of the insert in the vector was verified by ampli-
fication using the reverse and T7 primers.
For cloning in pGEX-6P-1 expression vector, the PCR
products were double digested by EcoRI/NotI or BamHI/
NotI according to the cloned region. The double digestion
products were purified and ligated into a previously
EcoRI/NotI or BamHI/NotI linearised and purified vector
according to the cloned region, respectively. All enzymes
for molecular cloning were obtained from Invitrogen, and
assay conditions were made according to the manufac-
turer's instructions.
The ligation mixtures were transferred into E. coli Top10
competent cells using the CaCl2 method. The presence of
the appropriate insert was determined by PCR and by
restriction analysis. DNA products were analysed on a
standard 2% agarose gel containing ethidium bromide
(Sigma). DNA sequences were elucidated by the dideoxy-
nucleotide chain termination method according to a cycle
sequencing protocol using thermosequenase (Amersham
Pharmacia Biotech) with the DNA sequencer ABI PRISM
3100/3100-Avant Genetic Analyser. The identified posi-
tive colonies were grown in LB medium containing ampi-
cillin (100 μg/ml), and the recombinant plasmids were
isolated from bacteria cells using a plasmid extraction kit
(Promega). The isolated plasmids were then used to trans-
form E. coli strain BL21 (DE3) competent cells for expres-
sion purposes.
Expression of recombinant proteins
The E. coli BL21 (DE3) cells harbouring the recombinant
plasmids were grown at 37°C, to an optical density (OD)
of 0.6 at 600 nm, in 5 ml LB medium containing 100 μg/
ml ampicillin. In the case of the biotinylated fusion pro-
teins expressed using the PinPoint Xa-1 vector, 2 μM of
biotin were also included in the medium. The culture
medium was then adjusted to 1 mM isopropyl-β-D-thi-
ogalactopyranoside (IPTG) and incubation continued at
37°C for 3 hours.
For large scale expression, cells were grown in 500 ml of
the culture media in the same conditions as the small
scale expression, harvested by centrifugation at 6000 rpm
for 10 minutes and washed twice with PBS. Bacteria har-
bouring recombinant PinPoint Xa-1 plasmids, collected
by centrifugation, were resuspended in cell lysis buffer (50
mM Tris-HCl pH 7.5, 50 mM NaCl, 5% glycerol, 5 mM
phenyl-methyl-sulfonyl-fluoride (PMSF) and 1 mM benz-
amidine), those harbouring recombinant pGEX-6P-1
plasmids, collected by centrifugation, were resuspended
in PBS. The cells were sonicated to release intracellular
proteins and the extract was then centrifuged at 12000
rpm for 20 minutes to remove cell debris.
Purification of the recombinant proteins
Two methods of purification of the biotinylated fusion
proteins expressed using the PinPoint Xa-1 vector were
used. These proteins were first purified by affinity chroma-
tography using the SoftLink™ Soft Release Avidin Resin
(Promega) according to the manufacturer's instructions.
The clear supernatant was mixed with 1 ml of the resin
equilibrated with cell lysis buffer for 2 hours at room tem-
perature or overnight at 4°C with gentile agitation. The
crude extract-resin was then centrifuged at 800 g for 3
minutes, the supernatant was eliminated and the resin
was thoroughly washed with cell lysis buffer. Proteins
were then eluted with 5 mM biotin in the same buffer. The
second method of purification consisted in heating the
extract, obtained after cell lysis and centrifugation, at
70°C for 5 minutes. The denatured proteins were then
eliminated by centrifugation at 12000 rpm for 20 min-
utes.
For the purification of proteins expressed using the pGEX-
6P-1 vector, the clear supernatant was mixed with 1 ml of
the glutathione beads (Sigma) equilibrated with PBS for
30 minutes at room temperature. The crude extract-glu-
tathione beads were then centrifuged at 800 g for 3 min-
utes, the supernatant was eliminated and the resin was
then washed twice with 6 ml PBS. Proteins were then
eluted with 5 mM oxidized glutathione (Sigma) in PBS.BMC Microbiology 2008, 8:217 http://www.biomedcentral.com/1471-2180/8/217
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Purified protein concentration was determined as
described by Bradford [38] using bovine serum albumin
(BSA) as standard.
Polyacrylamide gel electrophoresis and Western blot analysis
Polyacrylamide gel electrophoresis of proteins (SDS-
PAGE) was performed in the presence of sodium dodecyl
sulfate (SDS) (0.3 M) and β-mercaptoethanol (0.25 M), as
described by Laemmli [39]. Proteins were dissolved in
SDS sample buffer and boiled for 2 minutes. These pro-
teins were separated by SDS-PAGE in 15% gels containing
3% stacking gel and transferred to a nitrocellulose mem-
brane by electroblotting. The membrane was stained with
ponceau S in order to visualize the protein markers and
blocked with the TBST buffer (10 mM Tris-HCl, pH 8.0,
150 mM NaCl, 0.05% Tween 20) for 1 hour at 37°C. The
membrane was then incubated, under gentile agitation,
for 30 minutes at 37°C with streptavidin alkaline phos-
phatase (Promega), to detect the biotinylated fusion pro-
teins expressed using the PinPoint Xa-1 expression vector.
The membrane was washed three times with TBST for 5
minutes and rinsed briefly with deionized water. Finally,
the biotinylated proteins were visualized after staining
with western blue stabilized substrate for alkaline phost-
hatase (Promega) for 30 minutes.
Serology
Sera
A set of 244 sera was assembled, comprising 24 sera from
patients that were MIF positive to only C. trachomatis anti-
gens, 72 sera from a high risk population of prostitutes,
112 sera from healthy blood donors and 44 sera from
patients referred to sexually transmitted infection (STI)
clinics suspected to have chlamydial infections diagnosed
by Cobas Amplicor test as PCR positive (n = 14) or PCR
negative (n = 30). In addition, a set of 52 sera from MIF
positive cases to C. pneumoniae and a control set of 52 chil-
dren, aged from 2 to 8 years whose sera were C. trachomatis
and C. pneumoniae MIF negative, were also included to
produce a panel of 356 sera. All these sera were tested by
MIF and ELISA. Only 18 sera were tested by western blot
analysis including 7 sera from healthy blood donors, 2
sera from prostitutes, 7 sera from patients MIF C. pneumo-
niae positive, 1 serum from patients MIF C. trachomatis
positive and 1 serum from patients C. trachomatis PCR
negative. All the subjects provided verbal informed con-
sent, and the study protocol was approved by our ethics
committee (Association d'Enregistrement et de Lutte Con-
tre le Cancer du Sud Tunisien).
Serological methods
MIF
Chlamydial IgG antibodies were determined as previously
described by Wang and Grayston [40]. C. trachomatis and
C. pneumoniae species specific IgG antibodies were meas-
ured by our in house MIF test using purified elementary
bodies of C. pneumoniae, IOL-207 strain, C. psittaci Loth
strain and C. trachomatis L2 strain, as antigens. These anti-
gens were produced in yolk sac membranes of infected
eggs. The sacs of uninfected eggs were used as negative
control. Slides were prepared as acetone fixed prepara-
tions of the purified antigens by experienced laboratory
technicians capable of maintaining all conditions equal
between test runs. The antigen densities for all experi-
ments were guaranteed by an optimal concentration of
elementary bodies. Sera were tested in serial twofold dilu-
tions for IgG from 1/16 to the end point in order to deter-
mine their IgG antibody titers. All MIF series included a
positive and a negative serum. Incubation time was 30
minutes with diluted sera and 30 minutes with 1:300 flu-
orescein isothiocyanate (FITC) conjugated anti-human
immunoglobulin (biorad) in a moisture chamber at
37°C. After each of these incubations, the slides were
washed twice for 5 minutes with PBS. The mounting fluid
for setting coverslips on the slides contained glycerol in
PBS buffer. All the slides were examined by two experi-
enced and independent readers using a fluorescent micro-
scope (Zeiss AxioStar Plus) with × 40 objective. In case of
discordant readings, the slides were assessed by a third
reader. Results were interpreted using the same micro-
scope and by the same experienced readers in the same
period.
Western blot analysis using human sera
After electrophoresis and transfer, the membrane was cut
into strips. These strips were blocked with the blocking
buffer (PBS supplemented with 5% dried milk powder)
and incubated with human sera as primary antibodies
diluted at 1:100 in blocking buffer for an additional hour
at 37°C. The secondary antibody (Horseradish Peroxy-
dase (HRP)-conjugated rabbit anti-human IgG (Dako))
was diluted 1:1000 and incubated with the strips for 1
hour at 37°C. The membranes were washed three times
with washing buffer (PBS, 0.05% tween 20) after each of
these incubations. Finally the strips were washed twice
with PBS and developed in the dark for 30 minutes with
0.07% 4-chloro-1-naphtol (Sigma) and 0.01% H2O2 in
PBS. The development was stopped by replacing the
development solution by distilled water.
ELISA
Maxisorp microliter 96 well ELISA plates (Nunc) were
coated with 60 μl of the antigen solution per well (4 μg/
ml) in PBS and incubated overnight at 4°C. The coating
solution was discarded before the ELISA plates were
blocked with 75 μl of 3% BSA in PBS and incubated for 1
hour at 37°C. The plates were washed three times with
PBS containing 0.05% tween 20 (washing buffer). Fifty μl
per well of serum samples diluted 1:50 in PBS were added
in duplicate and incubated for 1 hour at 37°C. In theBMC Microbiology 2008, 8:217 http://www.biomedcentral.com/1471-2180/8/217
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same way, 50 μl per well of the secondary antibody
(Horseradish Peroxydase (HRP)-conjugated rabbit anti-
human IgG (Dako)), diluted 1:10000, were added and
incubated for additional 1 hour at 37°C. Between each of
these incubations, the wells were washed three times with
washing buffer using a plate washer. The reaction was vis-
ualized with 50 μl tetramethyl benzidine (TMB) substrate
per well and incubated for 30 minutes at 37°C in the dark.
The development was stopped by adding 100 μl of 1 M
HCl solution per well. The results were read immediately
by photometric readings of the OD at 450 nm with a ref-
erence wavelength of 620 nm.
Statistics
All data were collected using standardized forms and were
analyzed by Epi-Info version 6 and SPSS version 11.
Results
Bioinformatics research
The percentage identities determination of the OmcB pro-
teins of C. trachomatis serovars and those of C. pneumoniae
and C. psittaci according to C. trachomatis serovar E are pre-
sented in table 1. Using the Needle program, the OmcB
protein of C. trachomatis serovar E, used as the reference
sequence, was found to share 97% identity with the OmcB
proteins of C. trachomatis serovars A, D, L1, L2 and L3;
98% identity with those of serovars B, C, G, H, I, J and K;
99% identity with that of serovar F and 100% identity
with that of serovar E. Lower identities were found with
the OmcB proteins of C. pneumoniae (71%) and C. psittaci
(70%).
The alignment of the OmcB sequences using the ClustalW
program helped us identify two regions conserved within
C. trachomatis serovars but varying between the chlamy-
dial species. The two regions are localized in the N-termi-
nal (Nt) and C-terminal (Ct) parts of the OmcB protein of
C. trachomatis spanning amino acids 1 to 104 and 377 to
417, respectively (fig 1).
Using the Needle program and the Nt region of the OmcB
protein of C. trachomatis serovar E as the reference
sequence, 9% and 8% identities were found with the
OmcB proteins of C. pneumoniae and C. psittaci, respec-
tively; 19% identity with the OmcB proteins of C. tracho-
matis  serovar E and F, and 18% with those of all the
remaining serovars. Using the same program, the Ct
region of C. trachomatis serovar E was found to share 7%
identity with all the OmcB proteins of C. trachomatis sero-
vars, 4% and 5% identities with the OmcB proteins of C.
pneumoniae and C. psittaci, respectively.
The immunogenicity analysis using the Antigenic pro-
gram indicated that the epitopes of the OmcB protein are
distributed throughout the protein (See additional file 1).
The selected Nt region contains 3 epitopes which are not
highly immunogenic according to their scores in the full
length OmcB protein antigenicity prediction classified in
the 14th, 19th and 24th positions. The selected Ct region
contains only 2 epitopes that are positioned at the third
and 6th places according to their scores in the full length
OmcB protein antigenicity prediction.
The predicted molecular weights of the Nt and Ct regions
were about 11.5 and 5.5 kDa, respectively.
Cloning of the selected Nt and Ct regions and expression 
of the recombinant proteins
The two selected regions by the bioinformatics tools were
successfully amplified and cloned into the PinPoint Xa-1
and pGEX-6P-1 expression vectors using the appropriate
restriction enzymes (table 2).
The recombinant plasmids were transferred to E. coli BL21
(DE3) for expression purposes. In total, 4 recombinant
plasmids were produced encoding 4 proteins: the BPT-Nt
and the BPT-Ct expressed using the PinPoint Xa-1 vector,
the GST-Nt and the GST-Ct expressed using the pGEX-6P-
1 vector, respectively for the Nt and Ct regions of the
OmcB protein. The expected molecular weights of these
four proteins were 24.5, 18.5, 35.5 and 29.5 kDa, respec-
tively. The SDS-PAGE and western blotting results showed
a concordance between the molecular weights of these
proteins and those expected by the bioinformatic tool.
The expression level of the Nt region was too low using
the two vectors as shown in figure 2A and 2B. Further-
more, the presence of these recombinant proteins was not
reproducible. On the contrary, the expression levels of the
BPT-Ct and the GST-Ct were high using the two vectors
(fig 2A and 2B). However, the recombinant proteins
expressed using the PinPoint Xa-1 vector were quickly
degraded even in presence of protease inhibitors.
The expression of the tags alone using the native vectors
was also investigated. As found with the BPT-Nt, the BPT
expression was too low and detectable only by western
blot (fig 2A). On the contrary, the GST was highly
expressed (fig 2B).
Since the expression of the Nt region failed to generate vis-
ible and reproducible proteins, the two constructs were
abandoned and all further steps were made only with the
Ct region.
Purification of the Ct recombinant proteins and the vector 
tags
All attempts made to purify the BPT-Ct and the BPT
according to the manufacturer's recommendations failed.
A simple heat treatment of the extract at 70°C for 5 min-BMC Microbiology 2008, 8:217 http://www.biomedcentral.com/1471-2180/8/217
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Multiple sequence alignment of the OmcB proteins of C. trachomatis, C. pneumoniae and C. psittaci Figure 1
Multiple sequence alignment of the OmcB proteins of C. trachomatis, C. pneumoniae and C. psittaci. The multiple 
sequence alignment was performed using the ClustalW program. The selected N-terminal and C-terminal regions, which rep-
resent a lesser degree of similarity, are boxed. Stars mark identical amino acid residues in all sequences in the alignment. 
Dashes represent gaps in the alignment introduced by the ClustalW program. Conserved amino acids are shaded dark grey and 
physico-chemical conserved amino acids are shaded in light grey.
C.pneumoniae      1 MSKLIRRVVTVLALTSMASCFASGGIEAAVAESLITKIVASAETKPAPVP-MTAKKVRLV 
C.psittaci        1 MSKLIRRVVTVLALTSMASSFASGKIEAAAAESLATRFIASTENADDNVFQATAKKVRFG 
C.trachomatis     1 MNKLIRRAVTIFAVTSVASLFASGVLETSMAEFTSTNVISLADTKAKDNTSHKSKKARKN 
consensus           * ***** **. *.**.** **** .*   **   *  .   .           ** *   
 
 
C.pneumoniae     60 RRNKQPVEQKSRGAFCDKEFYPCEEGRCQPVEAQQESCYGRLYSVKVNDDCNVEICQSVP 
C.psittaci       61 RNKNQRQEQKHTEAFCDKEFYPCEGGQCQPVDATQESCYGKMYCVRVNDDCNVEISQSVP 
C.trachomatis    61 HSKETLVDR--------KEVAPVHES--KATGPKQDSCFGRMYTVKVNDDRNVEITQAVP 
consensus           .      .         **  *            *.**.*..* *.**** **** * ** 
  
 
C.pneumoniae    119 EYATVGSPYPIEILAIGKKDCVDVVITQQLPCEAEFVSSDPETTPTSDGKLVWKIDRLGA 
C.psittaci      120 EYATVGSPYPIEILAVGKKDCVNVVITQQLPCEVEFVSSDPATTPTSDSKLIWTIDRLGQ 
C.trachomatis   110 EYATVGSPYPLEITATGKRDCADVIITQQLPCEAEFVRSDPATTPTADGKLVWKIDRLGQ 
consensus           **********.** * **.**  *.******** *** *** **** * **.* ***** 
 
 
C.pneumoniae    179 GDKCKITVWVKPLKEGCCFTAATVCACPELRSYTKCGQPAICIKQEGPDCACLRCPVCYK 
C.psittaci      180 GEKCKITVWVKPLKEGCCFTAATVCACPELRSYTKCGQPAICIKQEGPECACLRCPVCYK 
C.trachomatis   170 GEKSKITVWVKPLKEGCCFTAATVCACPEIRSVTKCGQPAICVKQEGPENACLRCPVVYK 
consensus           *.* *************************.** *********.*****. ******* **  
 
 
C.pneumoniae    239 IEVVNTGSAIARNVTVDNPVPDGYSHASGQRVLSFNLGDMRPGDKKVFTVEFCPQRRGQI 
C.psittaci      240 IEVCNTGSAIARNVVVDNPVPDGYTHASGQRVLSFNLGDMRPGDSKCFCVEFCPQKRGKV 
C.trachomatis   230 INVVNQGTAIARNVVVENPVPDGYAHSSGQRVLTFTLGDMQPGEHRTITVEFCPLKRGRA 
consensus           * * * *.****** *.******* * ******.* **** **. .   ***** .** 
 
 
C.pneumoniae    299 TNVATVTYCGGHKCSANVTTVVNEPCVQVNISGADWSYVCKPVEYSISVSNPGDLVLHDV 
C.psittaci      300 TNVATVSYCGGHKCSANVTTVVNEPCVQVNISGADWSYVCKPVEYTIVVSNPGDLKLYDV 
C.trachomatis   290 TNIATVSYCGGHKNTASVTTVINEPCVQVSIAGADWSYVCKPVEYVISVSNPGDLVLRDV 
consensus           **.***.****** .* ****.******* * ************* * ******* * ** 
 
 
C.pneumoniae    359 VIQDTLPSGVTVLEAPGGEICCNKVVWRIKEMCPGETLQFKLVVKAQVPGRFTNQVAVTS 
C.psittaci      360 VIEDTAPSGATILEAAGAEICCNKAVWCIKEMCPGETLQFKVVAKAQSPGKFTNQVVVKT 
C.trachomatis   350 VVEDTLSPGVTVLEAAGAQISCNKVVWTVKELNPGESLQYKVLVRAQTPGQFTNNVVVKS 
consensus           *. **   * *.*** *. * *** ** .**. ***.**.*.. .** ** ***.* * . 
 
 
C.pneumoniae    419 ESNCGTCTSCAETTTHWKGLAATHMCVLDTNDPICVGENTVYRICVTNRGSAEDTNVSLI 
C.psittaci      420 NSDCGTCTSCAEVTTHWKGLAATHMCVIDTNDPICVGENTVYRICVTNRGSAEDTNVSLI 
C.trachomatis   410 CSDCGTCTSCAEATTYWKGVAATHMCVVDTCDPVCVGENTVYRICVTSRGSAEDTNVSLM 
consensus            * ********* ** ***.*******.** **.************* ***********.  
 
 
C.pneumoniae    479 LKFSKELQPIASSGPTKGTISGNTVVFDALPKLGSKESVEFSVTLKGIAPGDARGEAILS 
C.psittaci      480 LKFSKELQPVSSSGPTKGTITGNTVVFDALPKLGSKESVEFSVTLKGIAPGDARGEAILS 
C.trachomatis   470 LKFSKELQPVSFSGPTKGTITGNTVVFDSLPRLGSKETVEFSVTLKAVSAGDARGEAILS 
consensus           *********.  ********.******* **.*****.********..  **********  
 
 
C.pneumoniae    539 SDTLTSPVSDTENTHVY 556 
C.psittaci      540 SDTLTVPVADTENTHVY 557 
C.trachomatis   530 SDTLTVPVSDTENTHIY 547 
consensus           ***** ** ******.*    
 BMC Microbiology 2008, 8:217 http://www.biomedcentral.com/1471-2180/8/217
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utes allowed the purification of the BPT-Ct to nearly 80%
(fig 2C). The BPT was also purified using the same proto-
col; however the purified BPT band was not visible in
SDS-PAGE but reactive in western blot. No further reactive
bands were observed by western blot analysis of the BPT
and the BPT-Ct using human sera.
Proteins expressed using the pGEX-6P-1 vector were puri-
fied efficiently using glutathione beads affinity chroma-
tography (fig 2D). 1100 μg of the GST-Ct and 28000 μg of
the GST have been obtained from 500 ml of the culture of
the positive colonies.
Assessment of the reactivity of the BPT-Ct, the GST-Ct and 
the vector tags by western blot
First, we investigated the reactivity of the OmcB Ct region
by western blot analysis using human sera. We, therefore,
included the purified tags as negative controls for each
serum. The reactivity of six sera to the BPT-Ct, the GST-Ct
and the vector tags alone is shown in figure 3A. Positive
sera to the Ct region reacted equally with the BPT-Ct and
the BPT. However for the GST-Ct, the sera did not show
any reactivity with the GST. The western blot results for
the 18 tested sera are summarised in table 3. The GST gen-
erated less reactivity with human sera than the BPT. Fur-
thermore, the GST and the GST-Ct were purified to
homogeneity. Consequently, the GST-Ct was retained for
its evaluation by ELISA using the 356 sera.
Assessment of the reactivity of the GST-Ct and the GST by 
ELISA
In order to assess the GST reactivity in ELISA and its effect
on the GST-Ct ELISA results, all sera were subjected to a
double ELISA using as antigens the GST and the GST-Ct.
The reactivity of each serum to each antigen was tested in
duplicate. Figure 3B shows the reactivity of the GST-Ct
according to that of the GST for the same serum. All sera
showed level of reactivity to the GST ranging from 0.03 to
2.58. So, the reactivity of each serum to the OmcB Ct
region was determined by the formula: net OD value of
the OmcB Ct ELISA = [mean OD value of the purified
GST-Ct] – [mean OD value of the purified GST alone].
Evaluation of the OmcB Ct antigen by ELISA
Reproducibility of the OmcB Ct ELISA test
The reproducibility of the ELISA test was determined by
analyzing 12 sera with low, medium and high reactivity to
the OmcB Ct region, run under the same conditions on
different days. The difference between the OD values for
each serum was lower than 20% (fig 4).
Table 2: Primer sequences, size and location of DNA fragments in the omcB gene.
Vector Region Primera Sequencesb Size of DNA fragment (bp) Location of DNA fragment 
(bp)c
PinPoint Xa-1 Nt F
R
CCCTACGAACAAACTCATCAG
AC
AACAAGCTTTTATTCAACATTA
CGATCA
312 1–312
U19 GTTTTCCCAGTCACGTTGTA
Ct F
R
§CGAGACTGTAAAGAACTGAA
TCCTG
AATAAGCTTTCAACAGGTACC
ACAGTCA
120 1131–1251
T7 TTGTGAGGGGATAACAATTTC
SF
R
GTGACGCGGTGCAGGGCG
ATTTAGGTGACACTATAG
pGEX-6P-1 Nt F
R
£ACCCGAATTCCCAATGAACA
AACTGATAAGAC
#AACGCGGCCGCTTATTCAAC
ATTACGATCA
312 1–312
Ct F
R
¥AGACGGATCCTGGACTGTG
AAAGAACTG
#AATGCGGCCGCTCAACAGG
TACCACAGTCA
120 1131–1251
SF
R
CCAGCAAGTATATAGCATGG
CCGGGAGCTGCATGTGTCAGA
GG
a: F, forward, R, reverse, S, sequencing primer. b: Listed 5'-3'. The sequences in bold are primers restriction enzymes used for cloning (§ :NruI, £: 
EcoRI,#: NotI, ¥:BamHI). c: Locations of DNA fragments are according to Genbank accession number [EMBL: X55903].BMC Microbiology 2008, 8:217 http://www.biomedcentral.com/1471-2180/8/217
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Expression and purification of the recombinant proteins and the vector tags Figure 2
Expression and purification of the recombinant proteins and the vector tags. All proteins of interest are indicated 
with arrows. (A): Immunoblot analysis of the BPT tagged proteins expressed using the PinPoint Xa-1 vector in E. coli BL21 
(DE3). Lane 1: molecular weight marker (broad range protein molecular marker, PROMEGA), lane 2: BPT (13 kDa), lane 3: 
BPT-Nt (24.5 kDa), lane 4: BPT-Ct (18.5 kDa). The star marks an endogenous biotinylated protein of 22.5 kDa expressed in E. 
coli cells. (B): SDS-PAGE (15%) analysis of GST tagged proteins expressed using the pGEX-6P-1 vector in E. coli BL21 (DE3). 
Lane 1: molecular weight marker, lane 2: GST (24 kDa), lane 3: GST-Nt (35.5 kDa), lane 4: GST-Ct (29.5 kDa). (C): SDS-PAGE 
(15%) analysis of the semi purified BPT-Ct by heat treatment. Lane 1: molecular weight marker, lane 2: 40°C 5 min, lane 3: 
55°C 5 min, lane 4: 70°C 5 min. (D): SDS-PAGE (15%) analysis of purified GST and GST-Ct. Lane 1: molecular weight marker, 
lane 2: purified GST, lane 3: purified GST-Ct.
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Determination of the cut off value of the OmcB Ct ELISA test
Using sera from the healthy blood donors, the cut off
value, calculated by the formula: mean OD value + two
standard deviations, was found to be 0.764.
Correlations between the MIF and OmcB Ct ELISA tests
The distribution of OmcB Ct ELISA indices for all sera,
according to the MIF IgG antibody titers, is shown in fig-
ure 5. The mean OD values were significantly correlated
with the MIF antibody titers (p < 0.01). However, a large
distribution of the ELISA indices was found at each MIF
titer. Using the optimized cut off value of the ELISA test,
the concordance between the MIF and ELISA tests was
found to be 73% (259/356). Twenty six sera (7%) were
positive by both tests; 233 (66%) negative by both tests;
83 (23%) positive by MIF but not by ELISA and 14 (4%)
positive only by ELISA. Using the MIF as the reference
method, the OmcB Ct ELISA has a high specificity
(94.3%) but a low sensitivity (23.9%) (table 4).
Performance of the OmcB Ct ELISA test in selected populations
The diagnostic value of the OmcB Ct ELISA was also
assessed in different populations (table 5). The specificity
of the OmcB Ct ELISA test was determined using sera from
children, aged from 2 to 8 years, positive sera to C. pneu-
moniae by MIF and sera from patients with negative detec-
tion of C. trachomatis by PCR and was found to be about
93%. Significant differences were found between the
mean OD value of each population and that of children (p
< 0.01). Furthermore, no significant difference was found
between the mean OD values of sera from patients MIF C.
trachomatis positive, patients MIF C. pneumoniae positive,
Immunoreactivity of the recombinant proteins and the vector tags Figure 3
Immunoreactivity of the recombinant proteins and the vector tags. (A): Immunoblot analysis of the BPT-Ct, the BPT, 
the GST-Ct and the GST using 6 human sera. Lane 1: purified BPT-Ct, lane 2: purified BPT, lane 3: purified GST-Ct, lane 4: 
purified GST. Each column represents the reactivity of one serum to the four antigens. Column 1 and 2: sera from healthy 
blood donors, column 3: serum from prostitute, column 4, 5 and 6: sera from MIF C. pneumoniae positive patients. (B): ELISA 
results using the GST and the GST-Ct as antigens obtained with the 356 sera. Each dot represents the GST-Ct reactivity 
according to that of the GST for the same serum.
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Table 3: Immunoblot results of the Ct recombinant proteins related those of the vector tags.
Vector Tag-Ct reactivity/Tag reactivity
PinPoint Xa-1 No. of sera BPT-Ct+/BPT+ BPT-Ct +/BPT- BPT-Ct -/BPT+ BPT-Ct -/BPT-
12 0 0 6
pGEX-6P-1 No. of sera GST-Ct+/GST+ GST-Ct+/GST- GST-Ct-/GST+ GST-Ct-/GST-
220 1 4
BPT: biotin purification tag expressed using the native PinPoint Xa-1 vector, BPT-Ct: the C-terminal (Ct) recombinant protein expressed using the 
PinPoint Xa-1 vector, GST: glutathione-S-transferase expressed using the native pGEX-6P-1 vector, GST-Ct: the C-terminal (Ct) recombinant 
protein expressed using the pGEX-6P-1 vector.BMC Microbiology 2008, 8:217 http://www.biomedcentral.com/1471-2180/8/217
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patients referred to STI clinics and from healthy blood
donors (fig 6).
The sensitivity of our test was determined using as refer-
ence the PCR test in patients C. trachomatis PCR positive
in whom 4 of the 14 (28.6%) showed antibodies against
the OmcB Ct region.
The seroprevalence of C. trachomatis antibodies using the
OmcB Ct ELISA test in prostitutes and in healthy blood
donors was 33% (24/72) and 2% (3/112), respectively.
Significant differences were found between the mean OD
value of each population and that of prostitutes (p < 0.01)
(fig 6).
Discussion
Bioinformatics tools have been reported to be promising
in the choice of specific and immunogenic epitopes. In
fact, Zhang et al. [41] identified several intertype specific
epitopes on human adenovirus hexon using genomic
alignment tools, antigenicity and 3-D structure prediction
programs. Most of the predicted epitopes were found in
the prepared synthetic peptides and recombinant pro-
teins. In another study, Xu et al. [42] obtained a high titer
and a good specificity of the anti-mouse AdipoR-1 poly-
clonal antibodies, following immunization using the
selected polypeptide by bioinformatics analysis through
the Antigenic, the AntigenProfiler and the ClustalW pro-
grams. In the same context, we evaluated the potential
utility of the in silico methods for the prediction of specific
and immunogenic regions in the OmcB protein of C. tra-
chomatis. We used the ClustalW computer program, which
generates multiple sequence alignment, in order to dimin-
ish the extent of cross reactions frequently seen with anti-
bodies raised against the OmcB protein of the chlamydial
species. This program allowed us to detect two regions in
the OmcB protein, localized in the Nt and Ct regions, with
high homology within C. trachomatis serovars and low
homology with those of the other chlamydial species
infecting humans. Mygind et al. [33] reported that in con-
trast to the Nt region of the OmcB protein covering
approximately 70 amino acids which is highly variable
among chlamydial species [31] showing homology values
ranging between 19 and 28%, the Ct region spanning
amino acids 87 to 547 is highly conserved.
Synthetic peptides mimicking epitopes, as well as antipep-
tide antibodies, have many applications in the diagnosis
of various human diseases [43-45]. During the last 25
years, immunoinformatic software and databases for B
cell epitope prediction have been developed to facilitate
epitope design that could be synthesized and used instead
of the antigen. These programs focused essentially on lin-
ear epitope prediction and were based upon various
amino acid properties including beta turn prediction [46],
Reproducibility of the OmcB Ct ELISA assay Figure 4
Reproducibility of the OmcB Ct ELISA assay. The fig-
ure shows OD values, at 450 nm, of the 12 tested sera 
obtained in two ELISA tests conducted on two different days. 
Each line indicates the reactivity of one serum on the two 
days. The differences between the OD values for all sera 
were less than 20%.
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Correlations between the MIF and OmcB Ct ELISA tests Figure 5
Correlations between the MIF and OmcB Ct ELISA 
tests. *: Number of tested sera at the corresponding MIF 
titer range. The mean OD values significantly correlated with 
the MIF antibody titers (p < 0.01).
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surface accessibility [47], flexibility [48] and hydrophilic-
ity [49]. In the current study, we have used the Antigenic
program of the Pasteur institute which is based on amino
acid frequencies in antigenic domains and chemistry, to
predict potentially immunogenic regions in a protein
[36]. The application of this method to a large number of
proteins allowed an accuracy of 75%. The immunogenic-
ity prediction according to the full length OmcB protein
indicates that the epitopes are distributed throughout the
protein and that the OmcB Ct region appears more immu-
nogenic than the Nt region. The latter was previously
found to be of limited immunogenicity in experimentally
immunized rabbits [31] as well as in humans, and thus of
little serodiagnostic use [33]. Whilst Mygind et al. [33]
Table 4: Performance of the OmcB Ct ELISA relative to the MIF test results.
Concordance (%) Sensitivity (%) Specificity (%) PPVa (%) NPVb (%)
OmcB Ct ELISA/MIF 72.7 (259/356) 23.9 (26/109) 94.3 (233/247) 65.0 73.7
a: PPV, positive predictive value, b: NPV, negative predictive value. For comparison of the OmcB Ct ELISA test relative to the MIF assay, sensitivity, 
specificity, PPV, and NPV were calculated by using two-by-two tables.
Performance of the OmcB Ct ELISA in selected populations Figure 6
Performance of the OmcB Ct ELISA in selected populations. MIF CT-CP+: patients MIF C. trachomatis negative C. 
pneumoniae positive, HBD: healthy blood donors, MIF CT+CP-: patients MIF C. trachomatis positive C. pneumoniae negative, STI 
patients: patients referred to sexually transmitted infection clinics. *: Number of tested sera according to the population 
tested. Significant differences were found between the mean OD values of the OmcB Ct ELISA of children's sera as well as 
prostitutes' sera in comparison with those of the other populations tested (p < 0.01). No significant difference was found 
between the mean OD values of sera from patients MIF C. trachomatis positive, patients MIF C. pneumoniae positive, patients 
referred to STI clinics and from healthy blood donors.
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failed to identify a species specific B cell epitope in the
OmcB protein of C. trachomatis, Goodall et al. [50]
described a species specific C. trachomatis T cell epitope
spanning amino acids 400 to 413 overlapping in 10 of its
14 amino acids with the Ct region identified in our study.
The Nt and Ct regions selected in this study were cloned
into two expression vectors in order to test their ability to
better express these regions. We also used different tags to
identify which of them generates less reactivity with
human sera. The expression level of the Nt region using
the two vectors was too low and the presence of the Nt
recombinant proteins was not reproducible. Recently, an
important decrease in the expression levels of the GST and
GST-fused proteins in both native and recombinant pGEX
vectors has been explained by the occurrence of a sponta-
neous deletion of 701 bp leading to the loss of the tac pro-
moter directing transcription [51]. In our study, a strong
degradation was noticed in the proteins expressed using
the PinPoint Xa-1 vector despite the presence of protease
inhibitors. The production of untagged biotinylated pro-
teins was also reported even after careful optimization of
the culture conditions [52,53]. In contrast to the Nt
region, the Ct region was well expressed using the two vec-
tors. Differential expression was noticed only with the
BPT-Ct as JM109 E. coli cells exhibit a tenth less expressed
protein than E. coli BL21 (DE3) (data not shown). As
opposed to the GST-Ct and to the GST, we could not
purify the BPT-Ct and the BPT by affinity chromatography
using different protocols [52,54]. Surprisingly, despite the
instability of the biotinylated fusion proteins, they have
been found to be heat treatment resistant at 70°C for 5
minutes. Increasing temperature or incubation time gives
minimal yield of these two proteins without eliminating
thermo-resistant contaminants (data not shown). This
property is buffer dependent and is probably related to
the amino acids content of these proteins. Immunogenic-
ity of the Ct region was first investigated by western blot
analysis that revealed discrepancies between the BPT-Ct
and GST-Ct results. These discrepancies were related to the
tag reactivity that was greater using the PinPoint Xa-1 vec-
tor than using the pGEX-6P-1 vector. Only a few reports
described the reactivity of biotinylated proteins with
human sera in which the biotinylated tag interfere with
the developed ELISA assays [53,55]. Different authors did
not notice any reactivity of the GST with human sera
[29,56,57]. Moreover, although GST derived from Schisto-
soma japonicum, the use of recombinant GST tagged pro-
tein detected only one of 88 sera from patients with
schistosomiasis [58]. In our study, a strong reactivity of
the GST was seen especially by ELISA in line with previous
reports [59,60]. Thus, we used the GST-Ct as antigen and
the GST as control in the ELISA as they were purified to
homogeneity and as the GST exhibits less reactivity with
human sera.
Several authors studied the humoral immune response to
the OmcB protein of the chlamydial species. Klein et al.
[29] performed a comparative serological analysis of sev-
eral surface antigens of C. trachomatis and C. pneumoniae
in immunoblot assays and noticed that the strongest and
most frequent reactions were observed towards the
recombinant OmcB proteins of both species. All MIF C.
pneumoniae positive sera reacted with the OmcB protein
from both species, whereas, MIF C. trachomatis positive
sera displayed OmcB reactivity at considerably less fre-
quency but with a significant degree of cross reaction with
antibodies to the OmcB of C. pneumoniae. In another
study, Mygind et al. [33] found that 95% of MIF C. tracho-
matis positive sera and 80% of MIF C. pneumoniae positive
sera showed significant antibody titers against C. trachom-
atis OmcB protein. Bas et al. [32] evaluated whether new
ELISA assays could improve the serological diagnosis of C.
trachomatis reactive arthritis and reported that the highest
sensitivity and the lowest specificity were obtained with
the OmcB protein that were 100% and 45%, respectively.
This low specificity was related to the antibodies' cross
reactivity as 42% of the patients had IgG antibodies' to C.
pneumoniae. Portig et al. [61] developed ELISA tests by
using recombinant OmcB proteins from both species and
reported that 75% of patients with urethritis and those
from a Gambian endemic region and 100% of patients
Table 5: Performance of the OmcB Ct ELISA in selected populations.
Reference test Population No. of sera ELISA+/ELISA- Specificity (%) Sensitivity (%)
MIF Children MIF CT-CP- 52 3/49 94.2 (49/52) NA
Adulte MIF CT-CP+ 52 3/49 94.2 (49/52) NA
Patients MIF CT+CP- 24 1/24 NA 4.7 (1/24)
PCR Patients PCR CT- 30 2/28 93.3 (28/30) NA
Patients PCR CT+ 14 4/14 NA 28.6 (4/14)
NA: not applicable, ELISA positivity: OD ≥ 0.764. Children MIF CT-CP-: children sera MIF C. trachomatis negative C. pneumoniae negative, patients 
MIF CT-CP+: patients MIF C. trachomatis negative C. pneumoniae positive, patients MIF CT+CP-: patients MIF C. trachomatis positive C. pneumoniae 
negative, Patients PCR CT-: patients that are C. trachomatis PCR negative, Patients PCR CT+: patients that are C. trachomatis PCR positive.BMC Microbiology 2008, 8:217 http://www.biomedcentral.com/1471-2180/8/217
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tested with active trachoma and patients with sexually
acquired arthritis were OmcB C. trachomatis positive. The
specificity of the OmcB protein was reported to be low as
the antibody titers were higher on the homologous pro-
tein in 76% of cases.
Using our developed ELISA test, a sensitivity of only
23.9% and a specificity of 94.3% were found relative to
the MIF test indicating that the use of the sequence align-
ment tool might be a useful method for identifying spe-
cies specific regions in an immunodominant antigen.
However, the two epitopes, located in the Ct region, of the
24 predicted in the full length OmcB protein account for
approximately 25% of the serological response detected
by MIF limiting the use of the developed ELISA test when
screening C. trachomatis infections.
When using selected populations, the same specificity was
found in children and in patients C. pneumoniae MIF pos-
itive. However, the mean OD value found in MIF C. pneu-
moniae positive sera was in the same range as those from
patients referred to STI clinics, from patients MIF C. tra-
chomatis  positive and from healthy blood donors. The
same results were obtained by Mygind et al. [33] who
reported that 80% of C. pneumoniae MIF positive sera
showed antibodies to C. trachomatis but did not show
lower amount of antibodies to the OmcB protein.
Only 2 of the 30 (7%) patients with C. trachomatis PCR
negative results were OmcB Ct ELISA positive. One of
them was found C. trachomatis PCR positive in the latest
sixth months indicating previous infection with the path-
ogen leading to persistent antibodies. Indeed, IgG anti-
bodies to C. trachomatis have been described to persist
over many years although titers decline in some situations
[62,63]. Furthermore, only 4 of the 14 (28%) patients C.
trachomatis PCR positive were OmcB Ct ELISA positive.
This low sensitivity detected in PCR positive patients is
probably due to the delayed seroconversion since the pro-
duction of antibodies occurs almost 9 to 32 days follow-
ing initiation of symptoms [64,65]. Portig et al. [61]
compared sera from patients with suspected C. trachomatis
infections whose vaginal or urethral swabs tests were neg-
ative or positive and found that positivity to the C. tracho-
matis OmcB antibodies was 15% and 75%, respectively. In
another study, Bas et al. [32] compared the performance
of the OmcB protein to other chlamydial proteins in
patients with acute C. trachomatis infection and reported
that this protein showed the highest sensitivity (89%) but
the lowest specificity (57%).
Conclusion
The results of our study demonstrated that recombinant
proteins should be used with caution since the vector tags
reactivity with human sera is frequently seen. Further-
more, the in silico prediction approach led to a high spe-
cificity by means of the developed OmcB Ct ELISA test,
however; its low sensitivity limit the use of the developed
ELISA when screening C. trachomatis infections.
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